Abstract
Several thyroid hormone preparations are currently available, including levothyroxine sodium (thyroxine), liothyronine (triiodothyronine), and desiccated thyroid extract, as well as a combination of levothyroxine sodium and liothyronine. Levothyroxine sodium monotherapy at an appropriate daily dose provides uniform levels of both thyroxine and triiodothyronine in the circulation without diurnal variation. Therefore, it is the preparation of choice in most patients with hypothyroidism of both the primary and central types. A normal thyrotropin (TSH) level of 1–2 mU/L is considered the determinant of optimal daily levothyroxine sodium dose in patients with primary hypothyroidism, whereas normal thyroxine and triiodothyronine levels in the mid or upper normal range may denote optimal replacement in patients with central hypothyroidism.
Optimal daily levothyroxine sodium dose may be determined according to serum TSH level at the time of diagnosis of primary hypothyroidism. Initial administration of close to the full calculated dose of levothyroxine sodium is appropriate for younger patients, reducing the need for follow-up visits and repeated laboratory testing for dose titration. In the elderly and in patients with a history of coronary artery disease (CAD), the well established approach of starting with a low dose and gradually titrating to the full calculated dose is always the best option. Levothyroxine sodium can and should be continued in patients receiving treatment for CAD. Even minor over-replacement during initial titration of levothyroxine sodium should be avoided, because of the risk of cardiac events. Chronic over-replacement may induce osteoporosis, particularly in postmenopausal women, and should also be avoided.
Similar content being viewed by others
Notes
The use of trade names is for product identification purposes only and does not imply endorsement.
References
Rees-Jones RW, Larsen PR. Triiodothyronine and thyroxine content of dessicated thyroid tablets. Metabolism 1977; 26(11): 1213–8
Larsen PR, Davies TF. Hypothyroidism and thyroidititis. In: Larsen PR, Kronenberg HM, Melmed S, et al., editors. Williams textbook of endocrinology. Philadelphia (PA): Saunders, 2003: 423–56
Ridgway EC, McCammon JA, Benotti J, et al. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine. Ann Intern Med 1972; 77: 549–55
Fish LH, Schwartz HL, Cavanaugh J, et al. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. N Engl J Med 1987; 316: 764–70
Blackshear JL, Schultz AL, Napier JS, et al. Thyroxine replacement requirements in hypothyroid patients receiving phenytoin. Ann Intern Med 1983; 99: 341–2
Bunevicius R, Kazanavicius G, Zalinkevicius R, et al. Effects of thyroxine as compared with thyroxine plus triiodothyronine in patients with hypothyroidism. N Engl J Med 1999; 340(6): 424–9
Walsh JP, Shiels L, Lim EM, et al. Combined thyroxine/liothyronine treatment dose not improve well-being, quality of life, or cognitive function compared to thyroxine alone: a randomized controlled trial in patients with primary hypothyroidism. J Clin Endocrinol Metab 2003; 88(10): 4543–50
Sawka AM, Gerstein HC, Marriott MJ, et al. Does a combination regimen of thyroxine (T4) and 3,5,3′-triiodothyroinine improve depressive symptoms better than T4 alone in patients with hypothyroidism? Results of a double-blind randomized, controlled trial. J Clin Endocinol Metab 2003; 88(10): 4551–5
Kaplan MM, Sarne DH, Schneider AB. In search of the impossible dream? Thyroid hormone replacement therapy that treats all symptoms in all hypothyroid patients. J Clin Endocinol Metab 2003; 88(10): 4540–2
Kabadi UM, Jackson T. Serum thyrotropin in primary hypothyroidism: a possible predictor of optimal daily levothyroxine dose in primary hypothyroidism. Arch Intern Med 1995; 155(10): 1046–8
Kabadi UM, Kabadi M. Serum thyrotropin in primary hypothyroidism: a reliable and accurate predictor of optimal daily levothyroxine dose. Endocr Pract 2001; 7(1): 16–8
Kabadi UM. Normal thyrotrophin response to intravenous thyrotrophin releasing hormone administration: the best index of optimal L-thyroxine therapy in primary hypothyroidism. Postgrad Med J 1985; 61(718): 685–8
Gow SM, Caldwell G, Toft AD. Relationship between pituitary and other target organ responsiveness in hypothyroid patients receiving thyroxine replacement. J Clin Endocrinol Metab 1987; 64(2): 464–70
McDermott MT, Haugen BR, Lezotte DC, et al. Management practices among primary care physicians and thyroid specialists in the care of hypothyroid patients. Thyroid 2001; 11(8): 757–64
Keating Jr FR, Parkin TW, Selby JB, et al. Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis 1961; 3: 364–81
Kabadi UM. ‘Subclinical hypothyroidism’: natural course of the syndrome during a prolonged follow-up study. Arch Intern Med 1993; 153(8): 957–61
Kabadi UM, Cech R. Normal thyroxine and elevated thyrotropin concentrations: evolving hypothyroidism or persistent euthyroidism with reset thyrostat. J Endocrinol Invest 1997; 20(6): 319–26
Stock JM, Surks MI, Oppenheimer JH. Replacement dosage of L-thyroxine in hypothyroidism: a re-evaluation. N Engl J Med 1974; 290(10): 529–33
Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor of atrial fibrillation in older persons. N Engl J Med 1994; 331(19): 1249–52
Uzzan B, Campos J, Cucherat M, et al. Effects on bone mass of long-term treatment with thyroid hormones: a meta-analysis. J Clin Endocrinol Metab 1996; 81(12): 4278–9
Grebe SK, Cooke RR, Ford HC, et al. Treatment of hypothyroidism with once weekly thyroxine. J Clin Endocrinol Metab 1997; 82(3): 870–5
Stathatos N, Wartofsky L. Perioperative management of patients with hypothyroidism. Endocrinol Metab Clin North Am 2003; 32(2): 503–18
Rosenbaum RL, Barzel US. Levothyroxine replacement dose for primary hypothyroidism decreases with age. Ann Intern Med 1982; 96(1): 53–5
Davis FB, LaMantia RS, Spaulding SW, et al. Estimation of a physiologic replacement dose of levothyroxine in elderly patients with hypothyroidism. Arch Intern Med 1984; 144(9): 1752–4
Kabadi UM. Variability of L-thyroxine replacement dose in elderly patients with primary hypothyroidism. J Fam Pract 1987; 24(5): 473–7
Kabadi UM. Influence of age on optimal daily levothyroxine dosage in patients with primary hypothyroidism grouped according to etiology. South Med J 1997; 90(9): 920–4
Burrow GN, Fisher DA, Larsen PR. Maternal and fetal thyroid function. N Engl J Med 1994; 331(16): 1072–8
Roti E, Minelli R, Salvi M. Clinical review 80: management of hyperthyroidism and hypothyroidism in the pregnant woman. J Clin Endocrinol Metab 1996; 81(5): 1679–82
Mandel SJ, Larsen PR, Seely EW, et al. Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 1990; 323(2): 91–6
Arafah BM. Increased need for thyroxine in women with hypothyroidism during estrogen therapy. N Engl J Med 2001; 344(23): 1743–9
Isley WL. Effect of rifampin therapy on thyroid function tests in a hypothyroid patient on replacement L-thyroxine. Ann Intern Med 1987; 107(4): 517–8
Bongu D, Sachdev J, Kabadi UM. Effects of carbamazepine on the hypothalamic-pituitary-thyroid axis. Endocr Pract 1999; 5(5): 239–44
Acknowledgments
This preparation of this manuscript was funded by a grant from the Suvarnam Foundation Inc., Urbandale, Iowa, USA. The authors have no conflicts of interest directly relevant to the content of this review.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clarke, N., Kabadi, U.M. Optimizing Treatment of Hypothyroidism. Mol Diag Ther 3, 217–221 (2004). https://doi.org/10.2165/00024677-200403040-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00024677-200403040-00003